Login
EN
[EN] English
[FR] Français
Login
EN
[EN] English
[FR] Français
Give us feedback
Explore
Search
Special collections
Statistics
News
Help
Start on ORBi
Deposit
Profile
Publication List
Add your ORCID
Tutorials
Legal Information
Training sessions
About
What's ORBi ?
Impact and visibility
Around ORBi
About statistics
About metrics
OAI-PMH
ORBi team
Release Notes
Back
Home
Statistics
Statistics of A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)
Global
Last 12 months
Last 30 days
Contact ORBi